



**HAL**  
open science

## Steroidal lactams: A review

Malika Ibrahim-Ouali, Frédéric Dumur

► **To cite this version:**

Malika Ibrahim-Ouali, Frédéric Dumur. Steroidal lactams: A review. ARKIVOC - Online Journal of Organic Chemistry, 2022, 2022 (1), pp.262 - 284. 10.24820/ark.5550190.p011.773 . hal-03695077

**HAL Id: hal-03695077**

**<https://hal.science/hal-03695077>**

Submitted on 14 Jun 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Steroidal lactams: a review

Malika Ibrahim-Ouali<sup>\*a</sup> and Frédéric Dumur<sup>b</sup>

<sup>a</sup>Aix Marseille Univ, CNRS, Centrale Marseille, iSm2, F-13397 Marseille, France

<sup>b</sup>Aix Marseille Univ, CNRS, ICR, UMR 7273, F-13397 Marseille, France

Email: [malika.ibrahim@univ-amu.fr](mailto:malika.ibrahim@univ-amu.fr)


Received 04-19-2022

Accepted 05-24-2022

Published on line 06-06-2022

### Abstract

Steroidal lactams are also a class of steroid derivatives that were synthesized and modified to increase the biological activity of steroids. Their synthesis is a stimulating challenge to the scientist, often claiming the development of new and generally useful reactions. Some of them have been tested successfully as anticancer drugs against different types of leukemia. Recent developments in the syntheses of steroidal lactams are described herein. The biological activities of those steroidal derivatives for which data are available are given.



**Keywords:** Steroid, oxime, lactam moiety, Beckmann rearrangement

## Table of Contents

1. Introduction
2. Synthesis of Steroidal Lactams
3. Conclusions
4. Acknowledgements
5. References

### 1. Introduction

Steroids constitute an extensive and important class of biologically active polycyclic compounds that are widely used for therapeutic purposes.<sup>1-27</sup> Even after decades of research, the total synthesis of steroid nuclei by improved strategies continues to receive considerable attention. Numerous methods<sup>28-34</sup> have been exploited for the total synthesis of steroids which are widely distributed in nature, and which possess practical medical importance. Research into steroid total synthesis continues to this day.<sup>35-38</sup>

The introduction of heteroatom or replacement of one or more carbon atoms in a steroidal molecule by a heteroatom affects the chemical properties of that particular steroid and often results in alterations of its biological activities, which sometimes may be useful. Azasteroids especially express numerous biological activities. Studies of steroidal lactams revealed that the presence of the characteristic group (-NH-CO-) in the aza-steroid molecule is important in lowering the acute toxicity and improving the anticancer activity of the compounds.<sup>39</sup>

Moreover, steroidal lactams have attracted much interest, as many as 4-azalactams exhibiting strong inhibition of human steroid 5 $\alpha$ -reductase, making them potential drugs for the treatment of benign prostatic hyperplasia (BPH), acne, male pattern baldness, and alopecia.<sup>40</sup> Finasteride and turosteride are two commercial drugs belonging to this class.<sup>41-42</sup> Finasteride was the first 5 $\alpha$ -reductase inhibitor clinically approved in 1992 in the U.S. for the treatment of BPH. The 5 $\alpha$ -reductase inhibitory activity of these steroids is considered to be attributed to the lactam in ring A of the steroidal nucleus that mimics the intermediate transition state.<sup>43</sup>


This article provides an overview of the various synthetic strategies, which have been employed to synthesize steroidal lactams along with their biological properties, if provided, from the years 2011 to 2021. Although a previous review by Panda et al. has appeared in 2013 for heterocyclic steroids, some reports were missing from their compilation regarding steroidal lactams.<sup>44</sup> Thus, we have chosen to cover the aforementioned period on steroidal lactams.

### 2. Synthesis of Steroidal Lactams

In 2011, Zhou and coworkers<sup>45</sup> reported the synthesis of some steroidal lactams functionalized at the 6-position of the steroidal skeleton, using cholesterol as starting material. A series of 6-substituted-3-aza-A-homo-3-oxycholestanes and 6-substituted-4-aza-A-homo-3-oxycholestanes were prepared using the Beckman rearrangement as the key step.

The oxime **4** was isolated by four steps in 66.5% yield as depicted in Scheme 1.<sup>46</sup> The diketone **1** was selectively reduced to yield the crude alcohol **2**, which was directly oxidized to generate 3,6-diketone **3**. In the last step,


treatment of this derivative with hydroxylamine hydrochloride (1:1.1) in ethanol in the presence of sodium acetate led to compound **4**.



Reagents : a- $\text{NaBH}_4/\text{CH}_3\text{OH}$ ,  $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$  b- Jones' reagent, acetone, 88%;  
c-  $\text{NaAc} \cdot 3\text{H}_2\text{O}$ , 95%, ethanol,  $\text{NH}_2\text{OH} \cdot \text{HCl}$ , 90%.

### Scheme 1. Synthesis of steroidal oxime **4**.

A Beckmann rearrangement of **4** with  $\text{SOCl}_2/\text{THF}$  at  $0^\circ\text{C}$  led to steroidal lactams **5** and **6** with moderate yields. The major product was the 4-aza derivative **5** which was isolated in 45% yield (Scheme 2).




Reagents : a- $\text{SOCl}_2/\text{THF}$ ,  $0^\circ\text{C}$ , **5** (45%) and **6** (21.5%).

### Scheme 2. Synthesis of steroidal lactams **5** and **6**.

The steroidal lactams **7** and **11** were prepared by reduction using the reductant  $\text{NaBH}_4$  in methanol. The oximation of compounds **5** and **6** led to steroidal derivatives **8** and **12**, respectively, as depicted in Schemes 3


and 4. In the same way, the steroidal derivatives **9** and **10** were synthesized by treatment of compound **5** with thiosemicarbazide or semicarbazide adding a few drops of glacial acetic acid as a catalyst (Scheme 3).



Reagents : a-  $\text{NaBH}_4/\text{MeOH}$ , r.t.; b-  $\text{H}_2\text{NOH}\cdot\text{HCl}/\text{Na}_2\text{Ac}\cdot 3\text{H}_2\text{O}/\text{EtOH}$ , reflux;  
c-  $\text{H}_2\text{NC(S)NHNH}_2/\text{EtOH}$ , 60 °C; d-  $\text{H}_2\text{NC(O)NHNH}_2/\text{EtOH}$ .

**Scheme 3.** Synthesis of steroidal lactams **7-10**.






Reagents : a- $\text{SOCl}_2/\text{THF}$ ,  $0\text{ }^\circ\text{C}$ ; b-  $\text{K}_2\text{CO}_3/\text{MeOH}$ , r.t., 4h; c- Jones reagent/acetone, r.t., 2h;  
d-  $\text{NH}_2\text{OH}\cdot\text{HCl}$ ,  $\text{Na}_2\text{Ac}\cdot 3\text{H}_2\text{O}$ , EtOH, reflux.

### Scheme 5. Synthesis of steroidal lactams 15-18.

Similarly, steroidal lactams **23-26** exhibiting the 3-substituted-6-aza-B-homocholest-7-one key motif in their structures were prepared in 8 steps using cholesterol as starting material (Figure 6). The steroid derivative **19** was obtained using the procedure described in the literature.<sup>50</sup> The 3-keto steroid **22** was synthesized by oxidation of the alcohol **21** by Jones' reagent. Finally, the corresponding steroidal lactams **23-26** were isolated by reaction of compound **22** with  $\text{HONH}_2\cdot\text{HCl}$ ,  $\text{CH}_3\text{ONH}_2\cdot\text{HCl}$ ,  $\text{PhCH}_2\text{ONH}_2\cdot\text{HCl}$ , or thiosemicarbazide.




Reagents : a- $\text{SOCl}_2/\text{THF}$ , 0 °C; b-  $\text{K}_2\text{CO}_3/\text{MeOH}$ , reflux, 4h; c- Jones reagent/acetone, r.t., 2h;  
 d- 1-  $\text{NH}_2\text{OH}\cdot\text{HCl}$ ,  $\text{Na}_2\text{Ac}\cdot 3\text{H}_2\text{O}$ , EtOH, reflux; 2-  $\text{CH}_3\text{ONH}_2\cdot\text{HCl}$ , EtOH, 60 °C;  
 3-  $\text{PhCH}_2\text{ONH}_2\cdot\text{HCl}$ , EtOH, 60 °C; 4-  $\text{H}_2\text{NC(S)NHNH}_2\cdot\text{HCl}$ , EtOH, 60 °C.

### Scheme 6. Synthesis of steroidal lactams 23-26.

Finally, the authors were interested in the synthesis of compounds **28-32** having the structure of  $7\alpha$ -aza-B-homocholest-4(or 5)-ene to identify whether the aza position effects on the cytotoxicity of compounds (Scheme 7). Thus, the 3-acetoxy- $7\alpha$ -aza-B-homocholest-5-ene-7-one compound **28** was obtained by Beckman rearrangement of **27**. In addition, after oxidation by Jones reagent of compound **29**, migration of its 5,6 double bond into the more stable 4,5 double bond of compound **30** is observed. Then, the reaction of the  $\alpha,\beta$ -unsaturated derivative **30** with  $\text{HONH}_2\cdot\text{HCl}$  or thiosemicarbazide led to the steroidal lactams **31** and **32** respectively.

The authors studied the antiproliferative activity of the various synthesized compounds against HeLa, SGC-7901, GNE 2, Bel-7404, Tu 686, and SPC-A cell lines. They observed remarkable cytotoxic activity for steroidal lactams possessing 3-hydroximin, 3-hydroxyl, and 3-thiosemicarbazone groups. The derivatives which have proved to be the most potent anticancer agents are the steroids **16**, **21**, **23**, **26**, and **29** which, moreover, have an antiproliferative activity similar to that of cisplatin. In addition, by the annexin V staining test, the authors showed that compound **26** was able to effectively induce tumor cell apoptosis.




Reagents : a- $\text{SOCl}_2/\text{THF}$ ,  $0\text{ }^\circ\text{C}$ ; b-  $\text{K}_2\text{CO}_3/\text{MeOH}$ , reflux, 4h; c- Jones reagent/acetone, r.t., 2h; d-  $\text{NH}_2\text{OH}\cdot\text{HCl}$ ,  $\text{Na}_2\text{Ac}\cdot 3\text{H}_2\text{O}$ , EtOH, reflux; e-  $\text{H}_2\text{NC(S)NHNH}_2\cdot\text{HCl}$ , EtOH,  $60\text{ }^\circ\text{C}$ .

### Scheme 7. Synthesis of steroidal lactams 31-32.

In 2015, Cui and coworkers<sup>51</sup> reported the synthesis of a series of 3-substituted-6-aza-B-homo-5 $\alpha$ -stigmastan-7-one and 3-substituted-6-aza-B-homo-5 $\alpha$ -sitostan-7-one derivatives using stigmasterol and sitosterol as starting materials.

Scheme 8 outlines the synthetic procedures of compounds **34a-42a**, **34b-41b** and **43b**. Compounds **33a** and **33b** were prepared as reported previously.<sup>50</sup> The synthesis of compounds **34a** and **34b** was carried out by Beckmann rearrangement of **33a** and **33b** with  $\text{SOCl}_2/\text{THF}$  at  $0\text{ }^\circ\text{C}$ , and the acetylation of compounds **34a** and **34b** gave compounds **35a** and **35b**. Next, compounds **34a-34b** were converted to corresponding 3-carbonyl derivatives (**36a-36b**) *via* oxidation with PCC. The reaction of compounds **36a** and **36b** with  $\text{CH}_3\text{ONH}_2\cdot\text{HCl}$ ,  $\text{PhCH}_2\text{ONH}_2\cdot\text{HCl}$  or  $\text{HONH}_2\cdot\text{HCl}$  afforded the corresponding products **37a-39a** and **37b-39b**. The (*E*)- and (*Z*)-stereoisomer were obtained in preparation of **37a-38a** and **37b-38b**, respectively. Similarly, compounds **36a** and **36b** reacted with different 4-alkyl-3-thiosemicarbazide or 4-phenyl-3-thiosemicarbazide gave the 6-aza-7-oxo-B-homo-5 $\alpha$ -stigmastan-3-(alkyl)thiosemicarbazone derivatives **40a-42a** and 6-aza-7-oxo-B-homo-5 $\alpha$ -sitostan-3-alkyl(or phenyl)thiosemicarbazone derivatives **40b-41b** and **43b**.

Their antiproliferative activities against SGC 7901 (human gastric carcinoma), CNE (nasopharyngeal carcinoma), Bel 7404 (human liver carcinoma) and HeLa (human cervical carcinoma) cancer cells were assayed. The results showed that compounds with the side chain of sitosterol had better antiproliferative activity than compounds with the side chain of stigmasterol. The compound **40b** with 3-thiosemicarbazone and **41b** with 3-(40-methyl)thiosemicarbazone group displayed an excellent antiproliferative activity against Bel-7404 cells owning an IC<sub>50</sub> value of 3.9 and 5.6 μM, respectively (compared with cisplatin, IC<sub>50</sub>: 23 μM).




Reagents : a- SOCl<sub>2</sub>/THF, 0 °C; b- Ac<sub>2</sub>O/Pyridine; c- PCC, CH<sub>2</sub>Cl<sub>2</sub>; d- NH<sub>2</sub>OCH<sub>3</sub>.HCl 95%, NaOAc.3H<sub>2</sub>O, EtOH; e- PhCH<sub>2</sub>ONH<sub>2</sub>.HCl 95%, EtOH, NaOAc.3H<sub>2</sub>O; f- NH<sub>2</sub>OH.HCl 95%, NaOAc.3H<sub>2</sub>O, EtOH; g- H<sub>2</sub>NC(S)NHNH<sub>2</sub>.HCl, EtOH, AcOH; h- H<sub>2</sub>NC(S)NHNHCH<sub>3</sub>.HCl, EtOH, AcOH; i- H<sub>2</sub>NC(S)NHNHCH<sub>2</sub>CH<sub>3</sub>.HCl, EtOH, AcOH; j- H<sub>2</sub>NC(S)NHNHPh.HCl, EtOH, AcOH.

**Scheme 8.** Synthesis of steroidal lactams **34-43**.

In 2016, Sarli and coworkers<sup>52</sup> reported the evaluation and the synthesis of novel steroidal lactam derivatives, which are conjugated with 3-(4-(bis(2-chloroethyl)amino)phenoxy)propanoic acid (POPAM) **47** hoping to improve its biological activity. Four novel steroidal lactams related to POPAM **47** have been synthesized.


The first conjugate was prepared using testosterone **44** as starting material according to the known procedure of Camoutsis and Catsoulacos (Scheme 9).<sup>53</sup> Acetylation of testosterone with acetic anhydride in pyridine led to the corresponding acetate which was condensed with hydroxylamine to provide the *Z*- and *E*-oximes **45**. In a second step, a Beckman rearrangement of the mixture of **45** with  $\text{SOCl}_2$  in dioxane was realized and as predicted by previously described results,<sup>54</sup> a single lactam **46** was obtained in a moderate yield (63%) most likely due to *Z/E* isomerization before alkyl migration. Next, the acetyl moiety was deprotected under basic conditions with excellent yield (92%) and in a final step, the hydroxyl group at C-17 of the steroidal skeleton was esterified by POPAM **47** in the presence of DMAP and DCC in  $\text{CH}_2\text{Cl}_2$  to provide, with a quantitative yield, the desired conjugate ENGA-L06E **48**.



Reagents : a- 1-  $\text{Ac}_2\text{O}$ , DMAP, pyridine, 100%; 2-  $\text{NH}_2\text{OH}\cdot\text{HCl}$ , pyridine, 74%; b-  $\text{SOCl}_2$ , dioxane, 63%; c- POPAM, DCC, DMAP,  $\text{CH}_2\text{Cl}_2$ , 99%.

**Scheme 9.** Synthesis of ENGA-L06E **48**.

The second conjugate, ENGA-L08E **51** was isolated using estrone **49** as starting material as depicted in Scheme 10. The methodology of Liao and coworkers<sup>55</sup> was used to synthesize the 17 $\alpha$ -aza-D-homoestrone derivative **50**. Then, esterification of lactam **50** with POPAM **47** in DMF in the presence of DCC and DMAP led to the corresponding ester **51** in good yield.




Reagents : a- 1- NH<sub>2</sub>OH.HCl, pyridine, 100%; 2- SOCl<sub>2</sub>, dioxane, 56%;  
 b- POPAM **36**, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 68%.

#### Scheme 10. Synthesis of ENGA-L08E **51**.

The other two steroidal lactams **57** and **61** were prepared *via* the novel monolactam **56** and dilactam **60** using adrenosterone as starting material.

The monolactam **56** was prepared as depicted in Scheme 11. Firstly, according to Morreal,<sup>56-58</sup> a regioselective reduction of the 17-keto group of the D-ring of adrenosterone was done with NaBH<sub>4</sub>/MeOH to provide the corresponding alcohol, which was used without further purification in the next step. Next, the hydroxyl group at C-17 was protected into its corresponding acetate **53** in a yield of 90%. The treatment of this latter with NH<sub>2</sub>OH.HCl in pyridine led selectively to the desired oximes **54**, which by Beckman rearrangement provided the steroidal monolactam **55**. Finally, the C-17 position of compound **55** was deprotected followed by esterification with POPAM **47** to afford a yield of 96%, the desired conjugate ENGA-L07E **57**.



Reagents : a- 1- NaBH<sub>4</sub>, MeOH, 99%; 2- Ac<sub>2</sub>O, DMAP, pyridine, 96%; b- NH<sub>2</sub>OH.HCl, pyridine, 95%;  
c- SOCl<sub>2</sub>, dioxane, 62%; d- LiOH, MeOH, 100%; e- POPAM **47**, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 96%.


### Scheme 11. Synthesis of ENGA-L07E **57**.

A similar way was used to synthesize the bislactam alkylator **61**, as depicted in Scheme 12. A Beckmann rearrangement of oximes **58** led to the desired bislactam **59** in a 75% yield.

It is interesting to note that all new synthesized steroidal lactams with POPAM **47** performed relatively very low acute toxicities, together with important antileukemic activity *in vitro* and *in vivo*, producing a high therapeutic ratio.


In 2017, Montiel-Smith et al.<sup>59</sup> reported the synthesis of steroidal lactams starting from the easily available cholesterol and pregnenolone. A new procedure for the synthesis of a 6 $\alpha$ -aza-B-homo steroidal lactam analog of vespertilin, starting from diosgenin, was also described.

The synthesis of derivative **62** has been previously reported<sup>60</sup> from cholesterol by a synthetic route of five steps and polluting oxidants were used. Herein the formation of compound **62** was accomplished, in just one step, as depicted in Scheme 13 and the best yield of 65% was observed using 8 equivalents of BF<sub>3</sub>·OEt<sub>2</sub> and NaNO<sub>2</sub> and a 3:1 (v/v) Ac<sub>2</sub>O-AcOH ratio.



Reagents : a-  $\text{NH}_2\text{OH}\cdot\text{HCl}$ , pyridine, 50%; b-  $\text{SOCl}_2$ , dioxane, 75%;  
 c-  $\text{LiOH}$ ,  $\text{MeOH}$ , 93%; d- POPAM **47**, DCC, DMAP,  $\text{CH}_2\text{Cl}_2$ , 70%.


**Scheme 12.** Synthesis of ENGA-DL02E **61**.



Reagents : a-  $\text{NaNO}_2$ ,  $\text{BF}_3\cdot\text{Et}_2\text{O}$ ,  $\text{AcOH}$ ; b-  $\text{Na}_2\text{CO}_3$ ,  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ , reflux; c-  $\text{SOCl}_2$ , dioxane.

**Scheme 13.** Synthesis of steroidal lactam **64**.

The new protocol described above for cholesterol was applied with pregnenolone **65** possessing a ketone at C-20, as reported in Scheme 14. Using the same conditions, the steroidal derivative **66** was isolated without alteration of the carbonyl group in a 77% yield. In the next step, the (*Z*)-oxime **67** was obtained by treatment of compound **66** with sodium carbonate Na<sub>2</sub>CO<sub>3</sub>. Finally, the Beckmann rearrangement of steroidal oxime **67** was successfully performed using SOCl<sub>2</sub> in dioxane and the desired B-homo steroidal lactam **68** was isolated in only 3 steps, with an overall yield of 27%.



Reagents : a- NaNO<sub>2</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, AcOH; b- Na<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH, reflux; c- SOCl<sub>2</sub>, dioxane.


#### Scheme 14. Synthesis of steroidal lactam **68**.

Then, the authors used the same conditions to afford steroidal lactam **64** from oxime **63**, as depicted in Scheme 15.

Firstly, the nitroimino derivative **70a** was synthesized in a poor yield (22% yield) by a nitrosation reaction of diosgenin acetate **69a** using the conditions described by Iglesias.<sup>61</sup> Indeed, three side products were also obtained. The reaction was performed in AcOH with NaNO<sub>2</sub> (10 equiv) and BF<sub>3</sub>·OEt<sub>2</sub> (10 equiv) and the temperature (15–20 °C) was controlled over 4 h. No purification of the crude products was done to prevent the degradation of the side chain promoted by the silica gel and alumina.<sup>61</sup> A treatment of the mixture of compounds **70a** and **71a** was performed with NH<sub>2</sub>OH·HCl and NaOAc in refluxing ethanol to convert the ketone group and the nitroimino moieties of the main compounds into oximes.<sup>62</sup> The same treatment was applied to the mixture of derivatives **70b** and **71b**. The dioxime **72a** or **72b** was thus isolated without affecting the other functionalities (Scheme 14). In the next step, **72a** or **72b** was submitted under protic acidic conditions to a second-order Beckmann rearrangement to give in both cases vespertiline oxime **73**. The use of the mixture CF<sub>3</sub>COOH, Ac<sub>2</sub>O, BF<sub>3</sub>·OEt<sub>2</sub> at room temperature led to the best results in a very short reaction time (20 min.) and to the acetylation of the hydroxyl group at C-3 in compound **72b**. Next, treatment of compound **73** with Na<sub>2</sub>CO<sub>3</sub> in a 1:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub> refluxing solution led to the (*Z*)-oxime **74** without the ester group at C-5. In a final step,

the desired lactam **75** was isolated in a good yield of 70% using the same conditions described above for the synthesis of B-homo steroidal lactams **64** and **68**.

A panel of six human solid tumor cell lines was used to test the antiproliferative activity of these compounds. The authors observed that the most potent of all the derivatives assayed was compound **61a**, displaying slightly better GI50 values against WiDr and T-47D cancer cells when compared to cisplatin. A moderate activity in the cell lines screened was determined for the steroidal lactams **68** and **75**.




Reagents : a-  $\text{NaNO}_2$ ,  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ , AcOH; b-  $\text{NH}_2\text{OH} \cdot \text{HCl}$ , EtOH, reflux; c-  $\text{CF}_3\text{COOH}$ ,  $\text{Ac}_2\text{O}$ ,  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ ; d-  $\text{Na}_2\text{CO}_3$ ,  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ , reflux; e-  $\text{SOCl}_2$ , dioxane.

**Scheme 15.** Synthesis of steroidal lactam **75**.

In 2020, Liu et al.<sup>63</sup> reported the synthesis of biologically relevant steroidal spiro  $\beta$ -lactams from dienamides through the cascade 4-endo *N*-cyclization/aerobic oxidation sequence.

The synthetic pathway is depicted in Scheme 16. Dienamides **77** were prepared from  $\alpha,\alpha$ -dicyanoalkene **76**, and aldehydes through the cascade reactions under mild conditions.<sup>64</sup> Then, treatment of compound **66** in the presence of NaH in THF at 0 °C under air atmosphere led exclusively to the unexpected steroidal spiro  $\beta$ -lactams **78** within 1 h. Surprisingly, an additional hydroxyl group was also introduced at the  $\alpha$  position of the  $\beta$ -lactam ring *via* the base-promoted aerobic oxidation. The above reactions proceeded selectively through the 4-endo *N*-cyclization in the presence of NaH, followed by the base-mediated aerobic oxidation under air. No 6-endo *N*-cyclization products, namely 2-piperidinones were observed. This approach has several advantages such as short reaction time and mild reaction conditions.




Reagents : a- ArCHO, cascade reaction;<sup>64</sup> b- NaH, THF, 0 °C, under air.

### Scheme 16. Synthesis of steroidal $\beta$ -lactam **78** from dienamide **77**.

In 2021, Hernandez-Linares et al.<sup>65</sup> reported the synthesis of new steroidal lactams **82** and **87** from diosgenin **79** (Scheme 17 and 18).

In the case of the steroidal derivative **71**, the synthetic pathway is depicted in Scheme 17. Firstly, oxidation of diosgenin with PCC and calcium carbonate in dichloromethane led to the  $\alpha,\beta$ -unsaturated compound **80** with a slightly improved yield (90%) compared to that described.<sup>66</sup> In the next step, this latter was oxidized using the oxidant reagent potassium permanganate-sodium periodate.<sup>67</sup> Thus, the use of permanganate provided the formation of 1,2-diol, which carbon-carbon bond was then cleaved to give a carboxylic acid group and a ketone, without degradation, leading to the desired derivative **81**.

In the final step, two techniques for the ring closure were used to obtain the targeted steroidal derivative **82**. In the first case, following the methodology reported by Jiang,<sup>67</sup> a conventional N source, ammonium sulfate in refluxing glacial acetic acid for 4 h, was attempted and the overall yield was improved from 39% to 63%. In the second case, focused microwave irradiation (FMWI)<sup>67</sup> was tried with ammonium acetate as a reagent, for 3 min, leading to a much higher yield of 75%, than that reported in previous works of 19%. Finally, the authors succeeded in increasing the yield to 94%, using 1 eq. of compound **70** with 3.8 eq. of ammonium acetate in acetic acid. The use of DMF instead of acetic acid decreased the yield to 71% and no reaction can be observed with ammonium hydroxide as an N source.



Reagents : a- PCC, CaCO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 5h; b- KMnO<sub>4</sub>, NaIO<sub>4</sub>, NaCO<sub>3</sub>, *t*-BuOH/H<sub>2</sub>O, 3.5 h, 89%; c- Method A: NH<sub>4</sub>SO<sub>4</sub>, AcOH, reflux, 4 h; Method B: NH<sub>2</sub>OAc, AcOH, reflux, 4h; Method C: NH<sub>2</sub>OAc, AcOH, MW, 180 °C, 3 min, 94%;


### Scheme 17. Synthesis of steroidal lactam **82**.

An oxidation reaction was tested with CrO<sub>3</sub> to obtain the lactam moiety in ring B, but the yield was low. The best yield of the allylic oxidation reaction was observed starting with diosgenin acetate as substrate and using the Collins reagent.<sup>68</sup> Thus, using compound **84**, which contains a ketone group, as a precursor, a ring expansion was done leading to the intermediary oxime **86**. In the next step, a Beckmann rearrangement was performed with SOCl<sub>2</sub> in THF, to provide the targeted 7-azasteroid **87** as depicted in Scheme 18.

Moreover, the by-product **85** with a carboxylic group, was isolated in addition to **84**. The treatment of enone **84** with NH<sub>2</sub>OH.HCl under reflux in an ethanol and sodium acetate solution for two hours led to the corresponding oxime with a yield of 91%. One equivalent of the enone for 1.5 eq. of NH<sub>2</sub>OH.HCl was used to obtain the best yield. Finally, the reaction of derivative **86** with a solution of thionyl chloride in THF for 4 h at 0 °C<sup>69</sup> provided the steroidal lactam-type enamide **87**.

A specificity to different types of cellular receptors in cancer cell lines tested, as well as significant antiproliferative activities, were observed for some of the synthesized compounds, depending on the structure and conformation. The steroidal lactam **82** inhibits cancer cells lines with the PR and ER $\alpha$  without showing cytotoxicity for lymphocytes of PHB; however, the derivative seco-ketoacid **81** does not inhibit cells with the receptors ER $\alpha$ , ER $\beta$ , and PR.

Moreover, it was observed that the steroidal lactam **87** inhibits the proliferation in MDA-MB-231 cell lines that do not express ER $\alpha$ , PR, or HER2 receptors, with IC50 values lower than 0.093  $\mu\text{g}/\text{mL}$ , showing that the route through which that bind to cells is different.



Reagents : a-  $\text{Ac}_2\text{O}$ , DMAP, reflux, 1 h, 85%; b- Method A:  $\text{CrO}_3$ ,  $\text{AcOH}/\text{H}_2\text{O}$ , 0  $^\circ\text{C}$ , 3 h; Method B: Collins reagent,  $\text{CH}_2\text{Cl}_2$ , r.t., 12 h, 71%; c-  $\text{NH}_2\text{OH}\cdot\text{HCl}$ ,  $\text{AcONa}$ ,  $\text{EtOH}$ , reflux, 2 h, 91%; d-  $\text{SOCl}_2$ ,  $\text{THF}$ , 0  $^\circ\text{C}$ , 4 h, 52%;

**Scheme 18.** Synthesis of steroidal lactam **87**.

### 3. Conclusions

The lactam moiety and the steroid nucleus are prevalent in drug molecules and natural products, the derivatives possessing such fragments always present diverse and interesting biological profiles. Presented here is up-to-date literature on the syntheses of steroid lactams reported during the last years. Several of these syntheses may be useful, and in most cases reporting the cytotoxicity of the tested compounds, there seems to be a link with the presence of the lactam moiety in the steroid skeleton. Currently, interest in steroids and related molecules continues because of the emerging bioactivity and structural diversity inherent in this class of compounds.

### 4. Acknowledgements

This work has been financially supported by the CNRS and the Ministère de l'Enseignement Supérieur et de la Recherche.

### 5. References

1. Zeelen, J. F. *Medicinal chemistry of steroids*; Elsevier: Amsterdam, Netherlands, 1990.
2. Trager, L. F. *Steroidhormone*; Springer: Berlin, 1977.
3. Biellmann, J. F. *Chem. Rev.* **2003**, *103*, 2019.  
<http://doi.org/10.1021/cr020071b>
4. Nising, C. F.; Bräse, S. *Angew. Chem. Int. Ed.* **2008**, *47*, 9389.  
<https://doi.org/10.1002/anie.200803720>
5. Hanson, J. R. *Nat. Prod. Reports* **2010**, *27*, 887.  
<https://doi.org/10.1039/C001262A>
6. Wilson, R. M.; Danishefsky, S. J. *J. Org. Chem.* **2006**, *71*, 8329.  
<https://doi.org/10.1021/jo0610053>
7. Kumar, K.; Waldmann, H. *Angew. Chem. Int. Ed.* **2009**, *48*, 3224.  
<https://doi.org/10.1002/anie.200803437>
8. Maurin, P.; Ibrahim-Ouali, M.; Santelli, M. *Eur. J. Org. Chem.* **2002**, *1*, 151.  
[https://doi.org/10.1002/1099-0690\(20021\)2002:1<151::AID-EJOC151>3.0.CO;2-F](https://doi.org/10.1002/1099-0690(20021)2002:1<151::AID-EJOC151>3.0.CO;2-F)
9. Maurin, P.; Ibrahim-Ouali, M.; Santelli, M. *Tetrahedron Lett.* **2001**, *42*, 847.  
[https://doi.org/10.1016/S0040-4039\(00\)02119-5](https://doi.org/10.1016/S0040-4039(00)02119-5)
10. Oumzil, K.; Ibrahim-Ouali, M.; Santelli, M. *Synlett* **2005**, *11*, 1695.  
<https://doi.org/10.1055/s-2005-869879>
11. Cachoux, F.; Ibrahim-Ouali, M.; Santelli, M. *Tetrahedron Lett.* **2001**, *42*, 843.  
[https://doi.org/10.1016/S0040-4039\(00\)02118-3](https://doi.org/10.1016/S0040-4039(00)02118-3)
12. Oumzil, K.; Ibrahim-Ouali, M.; Santelli, M. *Tetrahedron Lett.* **2005**, *46*, 5783.  
<https://doi.org/10.1016/j.steroids.2006.06.003>
13. Cachoux, F.; Ibrahim-Ouali, M.; Santelli, M. *Synlett* **2000**, *3*, 418.  
<https://doi.org/10.1055/s-2000-6534>
14. Oumzil, K.; Ibrahim-Ouali, M.; Santelli, M. *Tetrahedron* **2005**, *61*, 9405.  
<https://doi.org/10.1016/j.tet.2005.07.026>

15. Ibrahim-Ouali, M. *Tetrahedron Lett.* **2009**, *50*, 1607.  
<https://doi.org/10.1016/j.tetlet.2009.01.107>
16. Ibrahim-Ouali, M. *Tetrahedron Lett.* **2010**, *51*, 3610.  
<https://doi.org/10.1016/j.tetlet.2010.05.008>
17. Ibrahim-Ouali, M.; Romero, E. *Steroids* **2012**, *77*, 157.  
<https://doi.org/10.1016/j.steroids.2011.11.003>
18. Cachoux, F.; Ibrahim-Ouali, M.; Santelli, M. *Synth Commun* **2002**, *32*, 3549.  
<https://doi.org/10.1081/SCC-120014965>
19. Oumzil, K.; Ibrahim-Ouali, M.; Santelli, M. *Steroids* **2006**, *71*, 886.  
<https://doi.org/10.1016/j.steroids.2006.06.003>
20. Oumzil, K.; Ibrahim-Ouali, M.; Santelli, M. *Tetrahedron Lett.* **2005**, *46*, 5799.  
<https://doi.org/10.1016/j.tetlet.2005.06.150>
21. Ibrahim-Ouali, M.; Romero, E.; Bouleghlem, H. *Tetrahedron* **2011**, *67*, 3668.  
<https://doi.org/10.1016/j.tet.2011.03.080>
22. Ibrahim-Ouali, M.; Zoubir, J.; Romero, E. *Tetrahedron Lett.* **2011**, *52*, 7128.  
<https://doi.org/10.1016/j.tetlet.2011.10.108>
23. Ibrahim-Ouali, M.; Bouleghlem, H.; Aouf, N. E. *Tetrahedron Lett.* **2012**, *53*, 1859.  
<https://doi.org/10.1016/j.tetlet.2012.02.005>
24. Ibrahim-Ouali, M.; Romero, E.; Hamze, K. *Steroids* **2012**, *77*, 1092.  
<https://doi.org/10.1016/j.steroids.2012.04.004>
25. Ibrahim-Ouali, M.; Romero, E. *Steroids* **2013**, *78*, 651.  
<https://doi.org/10.1016/j.steroids.2013.03.004>
26. Ibrahim-Ouali, M.; Hamze, K. *Steroids* **2014**, *80*, 102.  
<https://doi.org/10.1016/j.steroids.2013.12.002>
27. Ibrahim-Ouali, M. *Steroids* **2015**, *98*, 9.  
<https://doi.org/10.1016/j.steroids.2015.02.014>
28. Ibrahim-Ouali, M. *Steroids* **2006**, *71*, 1025.  
<https://doi.org/10.1016/j.steroids.2006.09.006>
29. Ibrahim-Ouali, M. *Steroids* **2007**, *72*, 475.  
<https://doi.org/10.1016/j.steroids.2007.03.004>
30. Ibrahim-Ouali, M.; Rocheblave, L. *Steroids* **2008**, *73*, 375.  
<https://doi.org/10.1016/j.steroids.2007.12.013>
31. Ibrahim-Ouali, M. *Steroids* **2008**, *73*, 775.  
<https://doi.org/10.1016/j.steroids.2008.04.005>
32. Ibrahim-Ouali, M. *Steroids* **2009**, *74*, 133.  
<https://doi.org/10.1016/j.steroids.2008.10.012>
33. Ibrahim-Ouali, M.; Dumur, F. *Arkivoc* **2017**, 202.  
<https://doi.org/10.24820/ark.5550190.p009.986>
34. Ibrahim-Ouali, M.; Dumur, F. *Arkivoc* **2019**, 304.  
<https://doi.org/10.24820/ark.5550190.p010.988>
35. Ibrahim-Ouali, M.; Dumur, F. *Arkivoc* **2021**, 130.  
<https://doi.org/10.24820/ark.5550190.p011.543>
36. Ibrahim-Ouali, M.; Dumur, F. *Arkivoc* **2021**, 300.  
<https://doi.org/10.24820/ark.5550190.p011.614>

37. Ibrahim-Ouali, M.; Dumur, F. *Arkivoc* **2021**, 471.  
<https://doi.org/10.24820/ark.5550190.p011.512>
38. Ibrahim-Ouali, M.; Dumur, F. *Arkivoc* **2022**, 140.  
<https://doi.org/10.24820/ark.5550190.p011.734>
39. Catsoulacos, P.; Politis, D.; Wampler, G.L. *Cancer Chemother. Pharmacol.* **1983**, *10*, 129.  
<https://doi.org/10.1007/BF00446225>
40. Metcalf, B.W.; Levy, M.A.; Holt, D.A. *Trends Pharm. Sci.* **1989**, *10*, 491.  
[https://doi.org/10.1016/0165-6147\(89\)90048-5](https://doi.org/10.1016/0165-6147(89)90048-5)
41. Liang, T.; Rasmusson, G.H.; Brooks, J.R. *J. Steroid Biochem.* **1983**, *19*, 385.  
[https://doi.org/10.1016/s0022-4731\(83\)80051-x](https://doi.org/10.1016/s0022-4731(83)80051-x)
42. Rasmusson, G.H.; Reynolds, G.F.; Steinberg, N.G.; Walton, E.; Pate, G.F.; Liang, T.; Cascieri, M.A.; Cheung, A.H.; Brooks, J.R.; Berman, C. *J. Med. Chem.* **1986**, *9*, 2298.  
<https://doi.org/10.1021/jm00161a028>
43. Georgianna, S.H.; Kozarich, J.W. *Curr. Opin. Chem. Biol.* **1997**, *1*, 254.  
[https://doi.org/10.1016/S1367-5931\(97\)80017-8](https://doi.org/10.1016/S1367-5931(97)80017-8)
44. Singh, R.; Panda, G. *Tetrahedron* **2013**, *69*, 2853.  
<https://doi.org/10.1016/j.tet.2013.02.018>
45. Huang, Y.; Cui, J.; Chen, S.; Gan, C.; Zhou, A. *Steroids* **2011**, *76*, 1346.  
<https://doi.org/10.1016/j.steroids.2011.06.013>
46. Cui, J.G.; Fan, L.; Huang, Y.M.; Xin, Y.; Zhou, A.M. *Steroids* **2009**, *74*, 989.  
<https://doi.org/10.1016/j.steroids.2009.07.009>
47. Huang, Y.; Cui, J.; Zheng, Q.; Zeng, C.; Chen, Q.; Zhou, A. *Steroids* **2012**, *77*, 829.  
<http://dx.doi.org/10.1016/j.steroids.2012.04.016>
48. Huang, Y.; Cui, J.; Chen, S.; Lin, Q.; Song, H.; Gan, C.; Su, B.; Zhou, A. *Mar. drugs* **2014**, *12*, 1715.  
<https://doi.org/10.3390/md12041715>
49. Cui, J.G.; Fan, L.; Huang, L.L.; Liu, H.L.; Zhou, A.M. *Steroids* **2009**, *74*, 62.  
<https://doi.org/10.1016/j.steroids.2008.09.003>
50. Cui, J.G.; Fan, L.; Huang, Y.M.; Xin, Y.; Zhou, A.M. *Steroids* **2009**, *74*, 989.  
<https://doi.org/10.1016/j.steroids.2009.07.009>
51. Cui, J.; Lin, Q.; Huang, Y.; Gan, C.; Yao, Q.; Wie, Y.; Xiao, Q.; Kong, E. *Med. Chem. Res.* **2015**, *24*, 2906.  
<https://doi.org/10.1007/s00044-015-1347-3>
52. Trafalis, D.; Geromichalou, E.; Dalezis, P.; Nikoleousakos, N.; Sarli, V. *Steroids* **2016**, *115*, 1.  
<http://dx.doi.org/10.1016/j.steroids.2016.07.009>
53. Camoutsis, C.; Catsoulacos, P. *J. Heterocyclic Chem.* **1983**, *20*, 1093.  
<https://doi.org/10.1021/ja01126a070>
54. Sugimoto, H.; Kaji, M.; Yamada, S. *J. Chem. Soc., Perkin Trans. 1* **1988**, 321.  
<https://doi.org/10.1039/P19880000321>
55. Yao, Z.; Xu, Y.; Zhang, M.; Jiang, S.; Nicklaus, M.C.; Liao, C. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 475.  
<https://doi.org/10.1016/j.bmcl.2010.10.112>
56. Zhao, Q.; Li, Z. *Steroids* **1994**, *59*, 190.  
[https://doi.org/10.1016/0039-128X\(94\)90027-2](https://doi.org/10.1016/0039-128X(94)90027-2)
57. Morreal, C.E. *Steroids* **1966**, *8*, 671.  
[https://doi.org/10.1016/0039-128X\(66\)90007-9](https://doi.org/10.1016/0039-128X(66)90007-9)
58. Norymberski, J.K.; Woods, G.F. *J. Chem. Soc.* **1955**, 3426.

- <https://doi.org/10.1039/JR9550003426>
59. Martínez-Pascual, R.; Meza-Reyes, S.; Vega-Baez, J. L.; Merino-Montiel, P.; Padrón, J. M.; Mendoza, Á.; Montiel-Smith, S. *Steroids* **2017**, *122*, 24.  
<https://doi.org/10.1016/j.steroids.2017.03.008>
60. Duddeck, H.; Frelek, J.; Szczepek, W.J.; Rodewald, W.J. *Bull. Chem. Soc. Ethiop.* **1987**, *1*, 18.
61. Y. López, K.M. Ruíz-Pérez, R. Yépez, R. Santillan, M. Flores-Alamo, M.A. Iglesias-Arteaga. *Steroids* **2008**, *73*, 657.  
<http://dx.doi.org/10.1016/j.steroids.2008.02.003>
62. Ranise, A.; Bondavalli, F.; Schenone, P.; Mugnoli, A.; Pani, M. *J. Chem. Soc., Perkin Trans. 1* **1990**, 3053.  
<http://dx.doi.org/10.1039/P19900003053>.
63. Fanga, Y.; Liaoa, G.; Guoc, H.; Yub, B.; Hong-Min, Liu. *Steroids* **2020**, *159*, 108635.  
<https://doi.org/10.1016/j.steroids.2020.108635>
64. Yu, B.; Shi, X.J.; Ren, J.L.; Sun, X.N.; Fang, Y.; Ye, X.W.; Wang, M.M.; Yu, Q.; Liu, H.M. *Eur. J. Med. Chem.* **2013**, *66*, 171.  
<https://doi.org/10.1016/j.ejmech.2013.05.035>
65. Martínez-Gallegos, A.A.; Guerrero-Luna, G.; Ortiz-Gonzalez, A.; Cardenas-García, M.; Bernes, S.; Hernandez-Linares, M. G. *Steroids* **2021**, *166*, 108777.  
<https://doi.org/10.1016/j.steroids.2020.108777>
66. Shawakfeh, K.Q.; Al-Said, N.H. *Steroids* **2011**, *76*, 232.  
<https://doi.org/10.1016/j.steroids.2010.10.002>.
67. Jiang, Z.X.; Ye, J.Q.; Jiang, L.; Zhao, Y.S. *Steroids* **2005**, *70*, 690.  
<https://doi.org/10.1016/j.steroids.2005.03.009>.
68. Hamid, A.A.; Kaushal, T.; Ashraf, R.; Singh, A.; Chand Gupta, A.; Prakash, O.; Sarkar, J.; Chanda, D.; Bawankule, D.U.; Khan, F.; Shanker, K.; Aiyelaagbe, O.O.; Negi, A.S. *Steroids* **2017**, *119*, 43.  
<https://doi.org/10.1016/j.steroids.2017.01.001>.
69. Zhi, X.; Zhang, Y.; Huang, J.; Xu, H. *Sci. Rep.* **2017**, *7*.  
<https://doi.org/10.1038/s41598-017-04136-3>.

## Authors' Biographies



**Malika Ibrahim-Ouali** carried out her Ph.D. under the supervision of Professor Gramain in Clermont-Ferrand (France) in 1996. The work was focused on the synthesis of alkaloids. She was a postdoctoral fellow with Prof. Knochel (Humboldt fellowship) in 1996 in Germany where she got her first training in organometallic chemistry. In 1997, she joined Professor H. P Husson's group at the ICSN (Paris) as a postdoctoral researcher. Since 1998,

she is currently an Associate Professor at Aix-Marseille University, and her field of interest remains the total synthesis of natural compounds.



**Frédéric Dumur** received his Ph.D. in chemistry in 2002 from the University of Angers (France) under the supervision of Professor Pietrick Hudhomme. After Post-Doctoral studies at the University of Groningen (The Netherlands), Reims Champagne-Ardennes (France) and Versailles Saint-Quentin-en-Yvelines (France), he joined the Faculty of Sciences at Aix-Marseille University in 2008, where he is currently working as an Associate Professor. His research interests include the synthesis of phosphorescent dopants for OLEDs and photoinitiators of polymerization. He co-authored about 300 publications and 5 book chapters.

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)